These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 1444495)
1. [A case of jejunal vein thrombosis due to medroxyprogesterone acetate]. Nakagawa K; Toshima T; Momono S; Sasaki Y; Furusawa A; Sato T Gan To Kagaku Ryoho; 1992 Nov; 19(13):2259-61. PubMed ID: 1444495 [TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA]. Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496 [TBL] [Abstract][Full Text] [Related]
3. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524 [TBL] [Abstract][Full Text] [Related]
4. [A case of dural sinus thrombosis during the medication of medroxyprogesterone acetate]. Hitosugi M; Kitamura O; Takatsu A; Watanabe K; Kan S Nihon Hoigaku Zasshi; 1997 Dec; 51(6):452-6. PubMed ID: 9545761 [TBL] [Abstract][Full Text] [Related]
5. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. Zaucha R; SosiĆska-Mielcarek K; Jassem J Breast; 2004 Aug; 13(4):321-4. PubMed ID: 15325667 [TBL] [Abstract][Full Text] [Related]
6. [Phase II study of medroxyprogesterone acetate in advanced breast cancer]. Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264 [TBL] [Abstract][Full Text] [Related]
7. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer]. Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803 [TBL] [Abstract][Full Text] [Related]
8. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer]. Noguchi S; Yamamoto H; Inaii H; Koyama H Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936 [TBL] [Abstract][Full Text] [Related]
9. [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report]. Izumi M; Iino Y; Yokoe T; Inoue T; Yamada T; Kobayashi I; Andoh T; Yokota T; Iijima T; Morishita Y Gan To Kagaku Ryoho; 1994 Feb; 21(2):265-8. PubMed ID: 8311500 [TBL] [Abstract][Full Text] [Related]
10. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer]. Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681 [TBL] [Abstract][Full Text] [Related]
11. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Beex L; Rose C; Mouridsen H; Jassem J; Nooij M; Estape J; Paridaens R; Piccart M; Gorlia T; Lardenoije S; Baila L Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796 [TBL] [Abstract][Full Text] [Related]
12. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)]. Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567 [TBL] [Abstract][Full Text] [Related]
13. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate]. Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889 [TBL] [Abstract][Full Text] [Related]
15. [Mammary gland carcinoma treated by large-dose medroxyprogesterone acetate of which pulmonary metastases disappeared and a selection of hormone, chemoimmunological treatment]. Matsumoto S; Kutsuna T; Tann M; Mizuno Y; Shinohara M; Kimura T; Banno T; Yoshizaki S Gan To Kagaku Ryoho; 1989 Jul; 16(7):2457-9. PubMed ID: 2526619 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group. Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945 [TBL] [Abstract][Full Text] [Related]
17. [Two cases of advanced breast cancer effectively treated with chemoendocrine therapy and radiotherapy]. Kimura M; Hagiwara S; Hirose K; Shimokawa Y; Iwai K; Uemura K Gan To Kagaku Ryoho; 1994 Oct; 21(14):2505-8. PubMed ID: 7944499 [TBL] [Abstract][Full Text] [Related]
18. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications]. Mauriac L; Durand M; Bonichon F; Chauvergne J Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203 [TBL] [Abstract][Full Text] [Related]
19. [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis]. Fujitomi Y; Fujiyoshi K; Yasue K Gan To Kagaku Ryoho; 2000 Feb; 27(2):303-6. PubMed ID: 10700906 [TBL] [Abstract][Full Text] [Related]
20. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer]. Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]